KLAS Contact
Contact KLAS
Contact KLAS
2023 BEST IN KLAS
Preferences
Related Series
2019
2018
2011
Related Segments
Medication Inventory Management 2022
Insights from Advanced Users Reveal What Is Possible Today
Author
Jackson Tate
Author
Paul Warburton
Author
Doug VanWagenen
Current Time Inside Cache Tag Helper: 12/6/2023 10:33:51 AM and Model.reportId = 1612
Medication inventory represents tremendous hospital spend. Managing it well is crucial for patient safety and cost management, yet many healthcare organizations report they struggle to get the right tools and workflows in place, leading to high-touch, manual processes. To understand what is possible with medication inventory management today, KLAS spoke to organizations that have broadly adopted capabilities from BD, Epic, Omnicell, and Swisslog Healthcare. Based on the feedback from these advanced users, this report examines the breadth of capabilities in use today, how well the solutions integrate with various hardware components, and how well the vendors support their customers to drive key outcomes. Performance data from vendors’ general customer bases is also included for additional context.if you don't have a login, getting started is easy.
Key Findings
- Epic Advanced Users Validate More Out-of-the-Box Functionality Than Customers of Pharmacy-Focused Vendors
- Integration Progress Has Been Made; No One Is Yet at Ideal End State
- Swisslog Customers Struggle to Achieve Desired Outcomes
- Epic Provides Upfront Partnering as Well as Ongoing Alignment
Writer
Elizabeth Pew
Designer
Jessica Bonnett
Project Manager
Mary Bentley
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2023 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.